Oxford BioDynamics’ EpiSwitch® CRC Blood Test Accurately Detects both Cancer and Polyps (Business Wire)

A revolutionary blood test could transform how colorectal cancer is detected—without the need for invasive procedures. Oxford BioDynamics’ (OBD) EpiSwitch® No-Stool Test (NST) has shown 81% accuracy in detecting early-stage colorectal cancer and 82% accuracy in identifying precancerous polyps, according to a new multi-center clinical study published in Cancers journal.

With colorectal cancer affecting nearly 2 million people annually, early detection is critical. NST offers a minimally invasive, cost-effective alternative to traditional colonoscopy and stool-based screenings, which often lack sensitivity for early-stage disease.